And here's the agenda:
##
AI CORNER
##
PMWC 2027: A Detailed Guide to the Conference and Its Agenda
The Precision Medicine World Conference returns to Santa Clara January 27–29, 2027, bringing together researchers, clinicians, diagnostics developers, biotechnology companies, investors, and policy specialists. Its agenda spans artificial intelligence, cancer detection, advanced therapeutics, genomics, and emerging applications beyond oncology. For prospective attendees, the central attraction is the opportunity to examine how promising technologies become useful, accessible, and financially sustainable care. Precision Medicine World Conference, Jan. 27-29
What kind of conference is PMWC?
The Precision Medicine World Conference, usually called PMWC, is a three-day meeting about the science, technology, and business of tailoring healthcare to individual patients. Formerly known as the Personalized Medicine World Conference, it began in 2009 under founder and president Tal Behar, working with Stanford Health Care. The 2027 Silicon Valley meeting is scheduled for January 27–29 at the Santa Clara Convention Center, with Stanford, UCSF, and Yale identified as co-hosts. PMWC LLC organizes the event. pmwcintl.com
The conference brings several professional communities into the same setting. Academic investigators describe discoveries; biotechnology and diagnostics companies discuss development and commercialization; clinicians and health-system leaders consider adoption; investors evaluate opportunities; and policy specialists examine access and payment. That mixture gives the meeting particular relevance to people whose work crosses institutional boundaries. A laboratory developing a new assay, for example, may need conversations about clinical evidence, physician use, reimbursement, and financing as much as it needs feedback on the assay itself. pmwcintl.com
The organizers advertise more than 3,000 attendees, 400 speakers, and 150 sponsors for 2027. These are promotional figures rather than independently verified attendance totals. The announced speaker and honoree roster includes Emmanuelle Charpentier, David Baker, Mary-Claire King, Eric Lander, Fei-Fei Li, Andrew Ng, Eric Horvitz, and Daphne Koller. The breadth of that roster illustrates the conference’s combination of molecular medicine and computation. Precision Medicine World Conference, Jan. 27-29
The format includes five main tracks, two company showcase tracks, exhibits, award presentations, and networking receptions. The main tracks contain scientific, clinical, and industry discussions; showcases emphasize company technologies and projects. PMWC also offers a startup competition, renamed in 2026 to honor Atul Butte. Its commercial orientation is explicit and useful for interpreting the meeting: attendees will encounter research presentations alongside product positioning and business development. PMWC Precision Medicine World Conference
For a first-time visitor, the main practical challenge is selection. Multiple simultaneous sessions mean that even an attendee staying all three days will see only part of the program. Prospective participants would benefit from identifying a few central questions and arranging relevant meetings before arrival. A particularly strong use of PMWC is to connect a scientific development with the clinical and commercial decisions that determine whether it reaches patients.
The 2027 agenda
The advertised 15-part program consists of five main tracks, each with a different theme on each of the three days. The company showcases are additional. The following descriptions summarize the posted program as reviewed on October 29, 2026; individual sessions and speakers remain subject to change. pmwcintl.com
1. Advanced therapeutics
Track 1 progresses from engineered cell and gene therapies on Wednesday to immunotherapies and targeted treatments on Thursday, then genetic and RNA medicines on Friday. The program covers competing cell-therapy approaches, manufacturing, delivery into the body, treatment resistance, patient selection, genome editing, and RNA splicing. Listed participants across this area include Katy Rezvani, David Miklos, Antoni Ribas, Emmanuelle Charpentier, Adrian Krainer, and Randy Schekman. LinkedIn
The notable feature is the attention to development constraints. Manufacturing and delivery can determine whether a persuasive biological idea becomes a practical treatment. Sessions addressing individualized therapies also raise a consequential question: how much evidence and infrastructure can be shared across treatments that differ from one patient to another? For biotechnology executives and translational researchers, these discussions may offer more actionable information than a broad survey of new therapeutic mechanisms.
2. Artificial intelligence and computational medicine
Track 2 follows AI through three different settings: diagnosis on Wednesday, clinical deployment on Thursday, and drug discovery on Friday. Diagnostic topics include computational pathology, AI-supported companion diagnostics, genomic interpretation, and combinations of different data types. Thursday includes clinical agents, foundation models, real-world evidence, and AI governance. Friday features computational protein design and drug-development discussions, with David Baker and Daphne Koller among the advertised participants. PMWC Precision Medicine World Conference
This structure helps separate questions that are often bundled together under the label medical AI. A system that interprets a pathology image, one that supports clinical work, and one that proposes a drug target face different tests of usefulness. The clinical program’s inclusion of evaluation and governance suggests that deployment experience will be an important counterweight to demonstrations. Drug-discovery attendees can look for evidence about experimental validation and development success, beyond improvements in computational prediction.
3. Precision diagnostics
Track 3 offers an especially coherent three-day sequence for laboratory and diagnostics audiences. Wednesday addresses early detection and intervention, including risk-based screening, precancerous disease, and the integration of molecular and imaging signals. Its opening discussion reassesses the accomplishments and shortcomings of the first generation of early-detection approaches. The listed contributors include Victor Velculescu, Rebecca Fitzgerald, Nickolas Papadopoulos, and Phil Castle. PMWC Precision Medicine World Conference
Thursday turns to liquid biopsy for treatment selection and monitoring. Topics include whether molecular residual disease, or MRD, should guide additional treatment; how blood tests can identify response and resistance; how tissue, blood, and imaging information should be reconciled; and whether MRD can support accelerated drug approval. Max Diehn and Sarah-Jane Dawson are among the featured investigators. The drug-endpoint session lists Ash Alizadeh as chair and participants including Ola Landgren, Chris Hourigan, and Aparna Parikh. PMWC Precision Medicine World Conference
Friday expands beyond cancer to transplant monitoring, infectious-disease testing, and maternal and fetal health. It also addresses the clinical actionability and reimbursement of non-cancer blood tests. The posted agenda lists Bruce Quinn among the participants in that discussion, chaired by Gabriel Bien-Willner. PMWC Precision Medicine World Conference
The diagnostic track’s strongest analytical thread is the connection between a test result and a subsequent decision. Early detection raises questions about whom to test and what follows a positive result. Monitoring raises questions about when treatment should change. A drug-trial endpoint raises another question: what does a biomarker establish about treatment benefit? These distinctions make the track relevant to clinical-development and market-access teams as well as assay developers.
4. Genomic medicine and implementation
Track 4 begins with genomic diagnosis and broader measurement of human health, including unresolved genetic disease, population and newborn screening, and structural variants. Thursday focuses on implementing precision medicine across healthcare organizations. Friday examines aging, prevention, and healthspan, including metabolic interventions, biological measurements, and digital monitoring. Eventbrite
The Thursday implementation program deserves particular attention from readers concerned with adoption and reimbursement. A session titled “What Gets Covered and Why” lists Dan Knecht, Mike Montalto, Tamara Syrek Jensen, and Shane Mull. Other discussions address operating models, clinical decision support, and the transition from biomarker evidence to routine care. These topics recognize that clinical adoption requires coordinated changes in payment, information systems, and professional practice. PMWC Precision Medicine World Conference
The aging program warrants a different evaluative lens. Attendees can look for a clear account of what a proposed measure changes in clinical care, how an intervention will be evaluated, and which outcomes matter to patients. The inclusion of aging alongside established genomic medicine creates opportunities for comparison, but the maturity of the evidence will differ across individual applications.
5. Spatial biology and disease applications
The new fifth track covers spatial biology on Wednesday, autoimmune and inflammatory disease on Thursday, and neurology on Friday. Spatial biology studies cells and molecular signals in their tissue context. The program connects that approach with digital pathology and biomarker development, then considers immune-directed therapies and biomarkers across autoimmune disease. pmwcintl.com
Friday’s neurology program includes Alzheimer’s blood biomarkers, other neurodegenerative disorders, imaging, digital measurements, and barriers to broader clinical adoption. Henrik Zetterberg, David Holtzman, Li-Huei Tsai, and David Liebeskind are among the leaders highlighted in the organizer’s neurology materials. The stated emphasis on treatment selection and access makes this more than a survey of biomarker discovery. pmwcintl.com
The broader significance of this track is the extension of precision medicine into diseases where patient classification, treatment selection, and longitudinal monitoring are developing along different paths from oncology. Attendees interested in translating an approach from one specialty to another can examine which assumptions survive the move and which require new evidence.
What the agenda suggests about the field
Taken together, the program suggests a field increasingly occupied with the consequences of its own technical progress. More sensitive assays, richer biological data, and more capable AI systems expand what can be measured or predicted. The conference repeatedly returns to the harder question of what healthcare should do with that information. This is an interpretation of the agenda, rather than a claim that the scheduled discussions will resolve those problems.
Three connections are especially useful for prospective attendees.
First, diagnostics and therapeutics are becoming harder to discuss separately. A screening test needs a credible follow-up pathway; an MRD result needs a defined decision; a targeted therapy needs a workable patient-selection strategy. An attendee who crosses between the diagnostic and therapeutic tracks may gain more than one who stays within a familiar technology category.
Second, evidence is becoming a shared concern across AI, laboratory medicine, and health-system implementation. The relevant questions include whether a finding generalizes, whether it changes practice, and whether the resulting change benefits patients. Reimbursement discussions add a practical perspective: what evidence would justify paying for that use? The agenda offers opportunities to compare those standards across specialties, while leaving room to question whether a company’s preferred evidence answers the purchaser’s question.
Third, the expansion into aging, immunology, and neurology makes careful comparison of development stages essential. A scientific mechanism, a validated measurement, a clinically useful test, and an adopted service represent different achievements. The presence of all four at one conference can be informative, provided attendees keep those distinctions in view.
Who is likely to benefit?
PMWC appears particularly well suited to diagnostics developers, biotechnology leaders, translational researchers, investors, and professionals working on clinical implementation or market access. Its breadth may also benefit clinicians seeking a view of technologies moving toward their specialties. Attendees seeking extended instruction in one technical method, or a detailed course in Medicare coding and payment mechanics, should inspect individual sessions closely before deciding whether the program meets that narrower need.
The meeting is in person, with no livestream announced. A full conference pass covers all three days, the main and showcase tracks, exhibits, and receptions. Eligible recordings and slides are offered afterward, subject to speaker permission. The organizer does not offer separate one-day or exhibit-only passes and advertises reduced rates for eligible academic, government, nonprofit, and student attendees. Current prices and participation details are available through the registration page. PMWC Precision Medicine World Conference
For readers weighing the trip, the most useful test is whether the agenda brings together the people and questions needed for a current project. A short list of relevant sessions, several planned conversations, and time reserved to explore an adjacent field would give attendance a clear purpose.
## ##
Compare the agendas for 2024 and 2027..
###
Comparing 2024 and 2027 at the PMWC
Comparing PMWC’s 2024 and 2027 agendas reveals continuity, but a sharper emphasis on clinical decisions, implementation, and expanding precision medicine beyond its established domains.
The foundation remains recognizable: cell and gene therapies, oncology, liquid biopsy, genomic analysis, artificial intelligence, and commercial showcases. Neither AI nor implementation suddenly arrived in 2027. The 2024 program already included foundation models, computational pathology, deployment barriers, reimbursement, and real-world evidence. The change is one of specificity and organization.
AI shows the clearest evolution in vocabulary and ambition. In 2024, many sessions emphasized data sharing, harmonization, privacy, and exploring AI’s potential. By 2027, clinical agents, multimodal diagnostics, enterprise deployment, and governance occupy prominent positions. Drug discovery increasingly asks whether computational predictions survive experimental validation and improve development outcomes. The discussion has moved toward evaluating systems that institutions might actually purchase and operate.
Diagnostics similarly becomes more explicitly decision-oriented. The 2024 liquid-biopsy program surveyed clinical status, prevention, and multicancer detection. The 2027 agenda asks whether MRD should trigger additional treatment, when resistance should prompt a therapeutic switch, and how conflicting tissue, blood, and imaging results should be reconciled. MRD as an endpoint for accelerated drug approval receives explicit attention. Screening remains important, but its consequences and limitations receive more pointed examination.
Several subjects lose standalone prominence. Pharmacogenomics occupied an entire day in 2024, with substantial attention to standardization, education, ordering, and reimbursement; it persists in 2027 without comparable billing. Women’s health and biological sex differences also lose their dedicated day, although maternal and fetal diagnostics remain. Infectious disease and microbiome topics are redistributed into broader diagnostic and immunology programs. These are changes in conference emphasis, not evidence that the fields have stalled.
The largest expansion is a fifth main track covering spatial biology, precision immunology, and neurology. Aging and healthspan also gain a dedicated day. Therapeutics places greater emphasis on programmable medicines, delivery, and manufacturing.
Collectively, the agenda suggests growing interest in connecting biological measurements to interventions and workable care pathways. For returning attendees, the strongest reason to return is the opportunity to examine those connections across specialties, rather than simply revisit familiar technologies with newer examples.
